We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunomic partners with EpiVax and PharmaJet on COVID-19 vaccine.
- Abstract
The article informs that Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of novel coronavirus disease caused by SARS-Cov-2 coronavirus. It informs that Immunomic will work with leaders from EpiVax and PharmaJet, who have a wealth of immunology and vaccine delivery expertise.
- Subjects
COVID-19; COVID-19 vaccines; VACCINE development; IMMUNOMIC Therapeutics Inc.; PHARMAJET Inc.; EPIVAX Inc.
- Publication
Rhode Island Medical Journal, 2020, Vol 103, Issue 4, p66
- ISSN
0363-7913
- Publication type
Article